| Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||||||
Net income | |||||||||||
4,046 | 2,940 | 1,999 | 1,602 | 1,999 | 1,449 | 1,456 | 1,317 | 880 | 776 | -1,533 | 226 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation | |||||||||||
160 | 134 | 121 | 115 | 104 | 96 | 84 | 71 | 54 | 41 | 33 | 22 |
Amortization | |||||||||||
475 | 337 | 384 | 287 | 265 | 277 | 198 | 291 | 204 | 84 | 104 | 9 |
Impairment charges | |||||||||||
31 | 1,679 | 489 | 49 | 133 | 105 | 148 | 118 | - | - | - | - |
Allocation of prepaid royalties | |||||||||||
- | - | - | - | - | - | - | - | 47 | 36 | 10 | 0 |
Provision for accounts receivable allowances | |||||||||||
- | - | - | - | - | - | - | 6 | -2 | 2 | 6 | 9 |
Deferred income taxes | |||||||||||
32 | -1,330 | -344 | -33 | -272 | -246 | 100 | -85 | -103 | -26 | -104 | -10 |
Change in value of contingent consideration and success payments | |||||||||||
19 | -1,350 | 21 | -8 | 48 | 171 | 166 | -147 | -9 | - | - | - |
Gain on sale of business | |||||||||||
0 | 0 | 38 | 0 | 0 | - | - | - | - | - | - | - |
Net loss on sales of debt securities available-for-sale | |||||||||||
-18 | 61 | 7 | 84 | -5 | -7 | - | - | - | - | - | - |
Fair value adjustments on equity investments | |||||||||||
317 | 0 | 0 | - | - | - | - | - | - | - | - | - |
Acquired in-process research and development | |||||||||||
- | - | - | - | - | - | - | - | - | - | 1,740 | 0 |
Share-based compensation expense | |||||||||||
921 | 644 | 606 | 577 | 447 | 325 | 231 | 217 | 182 | 145 | 106 | 58 |
Equity in (gains) losses of affiliated companies | |||||||||||
- | - | - | - | - | - | - | - | - | -0 | 8 | 3 |
Share-based employee benefit plan expense | |||||||||||
33 | 34 | 40 | 35 | 40 | 32 | 19 | 20 | 14 | 11 | 8 | 5 |
Derivative, Gain (Loss) on Derivative, Net | |||||||||||
-3 | -72 | -169 | 25 | 54 | 8 | 79 | 0 | -47 | - | - | - |
Unrealized change in value of derivative instruments | |||||||||||
- | - | - | - | - | - | -71 | 47 | -57 | 9 | -8 | -0 |
Realized losses (gains) on marketable securities available for sale | |||||||||||
- | - | - | - | - | - | - | 3 | 11 | 31 | -1 | 6 |
Other, net | |||||||||||
15 | 24 | 10 | -26 | 9 | -11 | -11 | -15 | -3 | -8 | 2 | -0 |
Change in current assets and liabilities, excluding the effect of acquisitions and disposals: | |||||||||||
Accounts receivable | |||||||||||
178 | 236 | 222 | 305 | 166 | 101 | 30 | 263 | 234 | 122 | 107 | -47 |
Inventory | |||||||||||
-82 | 42 | 55 | 51 | 56 | 89 | 69 | -71 | -18 | -1 | 25 | -23 |
Other operating assets | |||||||||||
55 | 73 | -94 | 326 | -52 | 90 | -91 | 66 | 45 | 53 | 129 | -19 |
Assets held for sale, net | |||||||||||
- | - | - | - | - | - | - | - | -2 | - | - | - |
Accounts payable and other operating liabilities | |||||||||||
290 | 273 | 619 | 527 | 234 | 287 | 68 | 191 | 51 | 0 | -17 | 83 |
Income tax payable | |||||||||||
-393 | 2,229 | 301 | 362 | 39 | 57 | -455 | 95 | 78 | 39 | 69 | 157 |
Payment of contingent consideration | |||||||||||
22 | 0 | 9 | 0 | 14 | 75 | 0 | 23 | - | - | - | - |
Deferred revenue | |||||||||||
41 | 20 | 7 | 37 | 8 | 16 | 5 | -1 | 20 | 3 | 0 | -3 |
Net cash provided by operating activities | |||||||||||
5,171 | 5,246 | 4,165 | 2,785 | 2,806 | 2,225 | 2,018 | 1,776 | 1,181 | 909 | 182 | 477 |
Cash flows from investing activities: | |||||||||||
Proceeds from sales of debt securities available-for-sale | |||||||||||
3,388 | 5,872 | 633 | 3,800 | 2,175 | 3,642 | 1,743 | 2,175 | 3,931 | 2,258 | - | - |
Purchases of debt securities available-for-sale | |||||||||||
675 | 8,163 | 1,106 | 1,889 | 2,661 | 3,983 | 2,768 | 1,693 | 3,272 | 3,007 | - | - |
Proceeds from the sale of assets, net | |||||||||||
- | - | - | - | - | - | - | 93 | - | - | - | - |
Capital expenditures | |||||||||||
330 | 279 | 236 | 286 | 150 | 119 | 111 | 132 | 98 | 93 | 77 | 64 |
Proceeds from sales of equity investment securities | |||||||||||
96 | 116 | 15 | 92 | 0 | 0 | - | - | - | - | - | - |
Investment in affiliated companies | |||||||||||
- | - | - | - | - | - | - | - | - | 3 | 12 | 1 |
Purchases of equity investment securities | |||||||||||
249 | 410 | 307 | 273 | 67 | 47 | 30 | 59 | 14 | 13 | - | - |
Proceeds from sales of marketable securities available for sale | |||||||||||
- | - | - | - | - | - | - | - | - | - | 1,148 | 1,654 |
Purchases of marketable securities available for sale | |||||||||||
- | - | - | - | - | - | - | - | - | - | 835 | 2,547 |
Payments for acquisition of business, net of cash acquired | |||||||||||
8,648 | 0 | 0 | 7,695 | 710 | 0 | 352 | 0 | 2,652 | - | 746 | 0 |
Payment for acquisition of intangible asset | |||||||||||
- | - | - | - | - | - | 48 | 0 | - | - | - | - |
Other | |||||||||||
0 | 27 | 1 | 8 | 24 | 20 | -14 | 5 | 1 | -3 | -12 | 7 |
Purchases of investment securities | |||||||||||
- | - | - | - | - | - | - | - | - | - | 9 | 23 |
Net cash (used in) investing activities | |||||||||||
-6,418 | -2,891 | -1,002 | -6,259 | -1,438 | -528 | -1,553 | 377 | -2,107 | -856 | -522 | -990 |
Cash flows from financing activities: | |||||||||||
Payment for treasury shares | |||||||||||
6,096 | 3,833 | 2,160 | 3,257 | 2,975 | 2,764 | 2,043 | 2,188 | 183 | 209 | - | 0 |
Proceeds from short-term borrowing | |||||||||||
5,709 | 0 | 100 | 6,111 | 2,566 | 4,462 | 4,494 | 1,878 | - | - | - | - |
Principal repayments on short-term borrowing | |||||||||||
5,709 | 0 | 100 | 6,213 | 3,012 | 4,227 | 4,712 | 1,353 | - | - | - | - |
Proceeds from issuance of long-term debt | |||||||||||
4,452 | 3,468 | 0 | 7,913 | 2,470 | 1,479 | 1,486 | 0 | 1,237 | - | - | - |
Principal repayments on current portion of long-term debt | |||||||||||
0 | 1,904 | 0 | 514 | 0 | 0 | - | - | - | - | - | - |
Payment of contingent consideration | |||||||||||
0 | 0 | 8 | -9 | 10 | 1 | 0 | 0 | - | - | - | - |
Payment of contingent consideration | |||||||||||
40 | 0 | 41 | 0 | 25 | 225 | 0 | 156 | - | - | - | - |
Net proceeds from share-based compensation arrangements | |||||||||||
144 | 685 | 359 | 252 | 297 | 551 | 476 | 166 | 86 | 49 | 128 | 144 |
Excess tax benefit from share-based compensation arrangements | |||||||||||
- | - | - | - | 250 | 169 | 49 | 31 | 36 | 97 | 153 | 142 |
Net cash (used in) financing activities | |||||||||||
-1,540 | -1,584 | -1,834 | 4,283 | -417 | -553 | -248 | -1,622 | 1,177 | -61 | 281 | 287 |
Effect of currency rate changes on cash and cash equivalents | |||||||||||
8 | 72 | -39 | -51 | -63 | 0 | 14 | -23 | -2 | 17 | -67 | 3 |
Net increase (decrease) in cash and cash equivalents | |||||||||||
-2,779 | 843 | 1,290 | 758 | 887 | 1,144 | 230 | 508 | 248 | 9 | -125 | -221 |
Supplemental schedule of non-cash investing and financing activity: | |||||||||||
Change in net unrealized (gain) loss on debt securities available-for-sale | |||||||||||
-9 | 611 | -563 | -315 | 494 | 205 | 1 | -3 | -13 | -3 | 87 | -81 |
Fair value of contingent consideration issued in business combinations | |||||||||||
- | - | - | 166 | 1,060 | 0 | 171 | - | - | - | - | - |
Matured shares tendered in connection with stock option exercises | |||||||||||
- | - | - | - | - | - | - | -4 | -8 | -2 | -7 | -6 |
Supplemental disclosure of cash flow information: | |||||||||||
Interest paid | |||||||||||
689 | 539 | 527 | 243 | 196 | 90 | 48 | 50 | 1 | 1 | 3 | 6 |
Conversion of convertible notes | |||||||||||
- | - | - | - | - | - | - | - | - | - | 196 | - |
Income taxes paid | |||||||||||
1,165 | 475 | 373 | 361 | 294 | 291 | 469 | 93 | 121 | 70 | 29 | 0 |
Human Longevity | |||||||||||
Investment in Human Longevity, Inc. common stock | |||||||||||
0 | 0 | 40 | - | 90 | 0 | 0 | - | - | - | - | - |
Celularity | |||||||||||
Investment in Human Longevity, Inc. common stock | |||||||||||
0 | 22 | 0 | - | - | - | - | - | - | - | - | - |